Supplemental Consolidating Financial Information (Schedule Of Condensed Consolidating Statement Of Cash Flows) (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2015	Jun. 30, 2014	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Cash flows from operating activities
Net (loss) income	$ (62,463)	$ (204,599)	$ (75,397)	$ (233,844)	$ (349,300)	$ (78,200)	$ (151,100)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation			38,331	35,275
Amortization			6,480	7,609
Deferred rent expense			338	230
Deferred income taxes			(781)	378
Stock-based compensation			5	71
Provision for doubtful accounts	3,753	3,428	8,221	7,724
Gain on the sale of property and equipment			(243)	59
Loss on sale leaseback transaction				135
Impairment loss		182,000		182,000
Early extinguishment of debt	37,390		37,390
Equity initial public offering expenses		4,163		4,163
Gain on foreign currency transactions			38
Gain on foreign currency derivative contracts				(4)
Fair value adjustment of noncontrolling interest and earn-out liability	2,745	204	3,205	403
Fair value adjustment of embedded derivative	5,217		6,559
Amortization of debt discount			746	1,301
Amortization of loan costs			2,630	3,039
Equity interest in net loss (earnings) of joint ventures	(188)	97	(212)	135
Distribution received from unconsolidated joint ventures			106	106
Changes in operating assets and liabilities:
Accounts receivable and other current assets			(37,921)	(26,977)
Income taxes payable			1,649	(649)
Inventories			124	(439)
Prepaid expenses			(1,003)	3,096
Accounts payable and other current liabilities			2,395	13,857
Accrued deferred compensation			686	591
Accrued expenses / other current liabilities			19,690	11,610
Net cash provided by operating activities			13,036	9,869
Cash flows from investing activities
Purchase of property and equipment			(25,753)	(33,147)
Acquisition of medical practices			(25,611)	(40,843)
Restricted cash associated with medical practice acquisitions			4,001	(10,992)
Proceeds from the sale of property and equipment			1,122	73
Loans to employees			160	(410)
Purchase of noncontrolling interest - non-redeemable			(1,233)
Contribution of capital to joint venture entities				(620)
Proceeds from foreign currency derivative contracts				26
Premiums on life insurance policies			(670)	(450)
Change in other assets and other liabilities			(156)	(401)
Net cash used in investing activities			(48,140)	(86,764)
Cash flows from financing activities
Proceeds from issuance of debt			970,618	130,016
Principal repayments of debt			(911,717)	(41,759)
Repayments of finance obligation			(136)	(113)
Proceeds from issuance of noncontrolling interest			3,230	229
Proceeds from noncontrolling interest holders - redeemable and non-redeemable			743	1,250
Cash distributions to noncontrolling interest holders-redeemable and non-redeemable			(2,022)	(956)
Payments for contingent considerations			(12,184)
Payment of call premium on long term debt			(24,877)
Payments of costs for equity securities offering				(2,550)
Payments of loan costs			(25,626)	(967)
Net cash (used in) provided by financing activities			(1,971)	85,150
Effect of exchange rate changes on cash and cash equivalents			(10)	(35)
Net decrease in cash and cash equivalents			(37,085)	8,220
Cash and cash equivalents, beginning of period			99,167	17,462	17,462
Cash and cash equivalents, end of period	62,082	25,682	62,082	25,682	99,167	17,462
Parent [Member]
Cash flows from operating activities
Net (loss) income	(66,391)	(208,222)	(83,825)	(247,440)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Stock-based compensation			5	71
Equity initial public offering expenses		4,163		4,163
Fair value adjustment of noncontrolling interest and earn-out liability	3,083		3,083
Fair value adjustment of embedded derivative	5,217		6,559
Equity interest in net loss (earnings) of joint ventures	58,748	204,012	75,506	243,196
Changes in operating assets and liabilities:
Income taxes payable				644
Intercompany payable / receivable			(60,706)	2,659
Accounts payable and other current liabilities				(859)
Accrued expenses / other current liabilities			(6)
Net cash provided by operating activities			(59,384)	2,434
Cash flows from investing activities
Intercompany notes to / from affiliates			2,000
Net cash used in investing activities			2,000
Cash flows from financing activities
Payments of costs for equity securities offering				(2,550)
Net cash (used in) provided by financing activities				(2,550)
Net decrease in cash and cash equivalents			(57,384)	(116)
Cash and cash equivalents, beginning of period			65,541	161	161
Cash and cash equivalents, end of period	8,157	45	8,157	45	65,541	161
21C [Member]
Cash flows from operating activities
Net (loss) income	(57,975)	(204,489)	(75,506)	(243,694)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Deferred income taxes				(49)
Early extinguishment of debt	31,076		31,076
Gain on foreign currency derivative contracts				(4)
Amortization of debt discount			746	905
Amortization of loan costs			2,630	2,927
Equity interest in net loss (earnings) of joint ventures	5,271	181,789	1,554	199,226
Changes in operating assets and liabilities:
Accounts receivable and other current assets			(1,113)	(5)
Income taxes payable			(82)	(1,316)
Prepaid expenses			(28)	(42)
Intercompany payable / receivable			(46,568)	8,138
Accounts payable and other current liabilities			(194)	126
Accrued expenses / other current liabilities			(5,014)	89
Net cash provided by operating activities			(92,499)	(33,699)
Cash flows from investing activities
Restricted cash associated with medical practice acquisitions				2
Loans to employees				(1)
Intercompany notes to / from affiliates				(2,400)
Contribution of capital to joint venture entities				(2,370)
Distributions received from joint venture entities			196	293
Proceeds from foreign currency derivative contracts				26
Net cash used in investing activities			196	(4,450)
Cash flows from financing activities
Proceeds from issuance of debt			963,900	60,400
Principal repayments of debt			(820,050)	(23,500)
Proceeds from noncontrolling interest holders - redeemable and non-redeemable				1,250
Payment of call premium on long term debt			(18,563)
Payments of loan costs			(25,626)
Net cash (used in) provided by financing activities			99,661	38,150
Net decrease in cash and cash equivalents			7,358	1
Cash and cash equivalents, beginning of period			123	122	122
Cash and cash equivalents, end of period	7,481	123	7,481	123	123	122
Subsidiary Guarantors [Member]
Cash flows from operating activities
Net (loss) income	(4,300)	(182,081)	(1,394)	(199,374)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation			30,441	30,025
Amortization			4,335	5,053
Deferred rent expense			188	259
Deferred income taxes			(214)
Provision for doubtful accounts	2,036	2,566	4,362	5,357
Gain on the sale of property and equipment			(248)	84
Loss on sale leaseback transaction				135
Impairment loss		182,000		182,000
Early extinguishment of debt	6,314		6,314
Fair value adjustment of noncontrolling interest and earn-out liability	(110)	204	122	403
Amortization of debt discount				55
Equity interest in net loss (earnings) of joint ventures	(5,954)	(2,014)	(7,982)	6,102
Distribution received from unconsolidated joint ventures			106	106
Changes in operating assets and liabilities:
Accounts receivable and other current assets			(9,283)	(6,554)
Income taxes payable			(171)	(715)
Inventories			56	(609)
Prepaid expenses			(554)	2,018
Intercompany payable / receivable			91,504	(20,467)
Accounts payable and other current liabilities			1,950	11,585
Accrued deferred compensation			492	438
Accrued expenses / other current liabilities			18,429	10,995
Net cash provided by operating activities			138,453	26,896
Cash flows from investing activities
Purchase of property and equipment			(18,926)	(23,295)
Acquisition of medical practices			(17,661)	933
Restricted cash associated with medical practice acquisitions			4,001	(616)
Proceeds from the sale of property and equipment			1,081	28
Loans to employees			153	(424)
Intercompany notes to / from affiliates			1,213	(339)
Purchase of noncontrolling interest - non-redeemable			(1,233)
Contribution of capital to joint venture entities				(239)
Distributions received from joint venture entities			2,896	1,314
Premiums on life insurance policies			(475)	(297)
Change in other assets and other liabilities			(89)	95
Net cash used in investing activities			(29,040)	(22,840)
Cash flows from financing activities
Proceeds from issuance of debt			382	5,650
Principal repayments of debt			(84,290)	(8,083)
Repayments of finance obligation			(136)	(113)
Proceeds from issuance of noncontrolling interest				1,750
Proceeds from noncontrolling interest holders - redeemable and non-redeemable			743
Payments for contingent considerations			(12,184)
Payment of call premium on long term debt			(6,314)
Net cash (used in) provided by financing activities			(101,799)	(796)
Net decrease in cash and cash equivalents			7,614	3,260
Cash and cash equivalents, beginning of period			16,614	9,084	9,084
Cash and cash equivalents, end of period	24,228	12,344	24,228	12,344	16,614	9,084
Subsidiary Non-Guarantors [Member]
Cash flows from operating activities
Net (loss) income	7,957	6,503	16,058	8,284
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Depreciation			7,890	5,250
Amortization			2,145	2,556
Deferred rent expense			150	(29)
Deferred income taxes			(567)	427
Provision for doubtful accounts	1,717	862	3,859	2,367
Gain on the sale of property and equipment			5	(25)
Gain on foreign currency transactions			38
Fair value adjustment of noncontrolling interest and earn-out liability	(228)
Amortization of debt discount				341
Amortization of loan costs				112
Equity interest in net loss (earnings) of joint ventures	(7)		(20)	(9)
Changes in operating assets and liabilities:
Accounts receivable and other current assets			(27,525)	(20,418)
Income taxes payable			1,902	738
Inventories			68	170
Prepaid expenses			(421)	1,120
Intercompany payable / receivable			15,770	9,670
Accounts payable and other current liabilities			639	3,005
Accrued deferred compensation			194	153
Accrued expenses / other current liabilities			6,281	526
Net cash provided by operating activities			26,466	14,238
Cash flows from investing activities
Purchase of property and equipment			(6,827)	(9,852)
Acquisition of medical practices			(7,950)	(41,776)
Restricted cash associated with medical practice acquisitions				(10,378)
Proceeds from the sale of property and equipment			41	45
Loans to employees			7	15
Intercompany notes to / from affiliates			(3,213)	2,739
Premiums on life insurance policies			(195)	(153)
Change in other assets and other liabilities			(67)	(496)
Net cash used in investing activities			(18,204)	(59,856)
Cash flows from financing activities
Proceeds from issuance of debt			6,336	63,966
Principal repayments of debt			(7,377)	(10,176)
Proceeds from issuance of noncontrolling interest			3,230	468
Cash distributions to shareholders			(5,114)	(2,563)
Payments of loan costs				(967)
Net cash (used in) provided by financing activities			(2,925)	50,728
Effect of exchange rate changes on cash and cash equivalents			(10)	(35)
Net decrease in cash and cash equivalents			5,327	5,075
Cash and cash equivalents, beginning of period			16,889	8,095	8,095
Cash and cash equivalents, end of period	22,216	13,170	22,216	13,170	$ 16,889	$ 8,095
Eliminations [Member]
Cash flows from operating activities
Net (loss) income	58,246	383,690	69,270	448,380
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:
Equity interest in net loss (earnings) of joint ventures	$ (58,246)	$ (383,690)	(69,270)	(448,380)
Cash flows from investing activities
Contribution of capital to joint venture entities				1,989
Distributions received from joint venture entities			(3,092)	(1,607)
Net cash used in investing activities			(3,092)	382
Cash flows from financing activities
Proceeds from issuance of noncontrolling interest				(1,989)
Cash distributions to noncontrolling interest holders-redeemable and non-redeemable			(2,022)	(956)
Cash distributions to shareholders			5,114	2,563
Net cash (used in) provided by financing activities			$ 3,092	$ (382)